Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Entera Bio Ltd (ENTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: ENTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10
1 Year Target Price $10
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 10.07% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 83.63M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 1 | Beta 1.48 | 52 Weeks Range 1.41 - 2.79 | Updated Date 07/10/2025 |
52 Weeks Range 1.41 - 2.79 | Updated Date 07/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.26 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -6102.38% |
Management Effectiveness
Return on Assets (TTM) -39.6% | Return on Equity (TTM) -71.46% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 70824465 | Price to Sales(TTM) 375.03 |
Enterprise Value 70824465 | Price to Sales(TTM) 375.03 | ||
Enterprise Value to Revenue 317.6 | Enterprise Value to EBITDA -1.52 | Shares Outstanding 45452200 | Shares Floating 28901215 |
Shares Outstanding 45452200 | Shares Floating 28901215 | ||
Percent Insiders 23.97 | Percent Institutions 22.49 |
Upturn AI SWOT
Entera Bio Ltd
Company Overview
History and Background
Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on developing orally delivered large molecule therapeutics for unmet medical needs. Founded to address challenges in oral peptide and protein delivery, they are developing novel formulations to enhance absorption.
Core Business Areas
- Oral Peptide/Protein Delivery: Entera Bio is focused on developing and commercializing oral formulations of peptides and proteins, overcoming the challenges of gastrointestinal degradation and poor absorption associated with traditional injection-based therapies.
- Osteoporosis Treatment: The company's primary focus is on developing oral parathyroid hormone (PTH) analogs for the treatment of osteoporosis and related bone disorders.
Leadership and Structure
Entera Bio has a management team with experience in pharmaceutical development, regulatory affairs, and commercialization. Their organizational structure includes departments for research and development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- EB613 (Oral PTH): EB613 is Entera Bio's lead product candidate, an oral formulation of parathyroid hormone (PTH) for the treatment of osteoporosis. It aims to provide a convenient alternative to injectable PTH therapies. EB613 is currently in clinical development, with ongoing studies to evaluate its efficacy and safety. There is no market share data available as this is still under development. Competitors include injectable PTH therapies such as Eli Lilly's Forteo and Radius Health's Tymlos.
Market Dynamics
Industry Overview
The osteoporosis treatment market is characterized by a growing prevalence of the disease due to an aging population. The market is competitive, with established injectable therapies and emerging oral formulations seeking to address patient needs and improve adherence.
Positioning
Entera Bio aims to differentiate itself by offering an oral alternative to injectable PTH therapies, which could improve patient convenience and compliance. Their competitive advantage lies in their proprietary oral delivery technology, which enables the absorption of large molecules through the gastrointestinal tract.
Total Addressable Market (TAM)
The global osteoporosis market is projected to reach billions of dollars. Entera Bio aims to capture a significant portion of this market by offering a convenient oral therapy. Currently, since there is no product commercialized, the TAM share is small.
Upturn SWOT Analysis
Strengths
- Proprietary oral delivery technology
- Potential for improved patient compliance
- Experienced management team
Weaknesses
- Limited financial resources
- Clinical development risk
- Dependence on a single lead product candidate
Opportunities
- Growing osteoporosis market
- Potential partnerships with larger pharmaceutical companies
- Expansion into other therapeutic areas
Threats
- Competition from established therapies
- Regulatory hurdles
- Generic erosion of existing treatments
Competitors and Market Share
Key Competitors
- LLY
- RDUS
Competitive Landscape
Entera Bio competes with established pharmaceutical companies that market injectable osteoporosis therapies. Its advantage lies in the potential for oral delivery, but faces challenges related to clinical development and regulatory approval.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been characterized by preclinical and clinical development milestones. Investors assess the company's progress based on the advancement of its lead product candidate through clinical trials.
Future Projections: Future growth is dependent on the successful completion of clinical trials and regulatory approval of EB613. Analyst estimates vary depending on the perceived probability of success and market potential.
Recent Initiatives: Recent initiatives include ongoing clinical trials of EB613, presentations at scientific conferences, and efforts to secure partnerships and funding.
Summary
Entera Bio is a clinical-stage biopharmaceutical company focused on oral delivery of large molecules, primarily for osteoporosis treatment. While their proprietary technology presents a potential advantage, they face significant clinical development risks and competition from established therapies. Their success hinges on positive clinical trial results for EB613. The company needs to continue securing funding to advance its clinical programs.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC filings
- Analyst reports
- Company presentations
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Please consult with a qualified financial advisor before making any investment decisions. Market share data is estimated and may not be precise. Financial data is as of the latest available information from public sources.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Entera Bio Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2018-06-28 | CEO & Director Ms. Miranda J. Toledano M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 18 | Website https://www.enterabio.com |
Full time employees 18 | Website https://www.enterabio.com | ||
Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial for the treatment of post-menopausal women with low bone mineral density and high-risk osteoporosis; and has completed Phase 1 clinical trial to treat stress fractures. In addition, the company is developing EB612, a tablet peptide replacement therapy for hypoparathyroidism. Further, it develops oral oxyntomodulin (OXM), a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity and metabolic disorders; and GLP-2 peptide tablet as an injection-free alternative for patients suffering from rare malabsorption conditions, such as short bowel syndrome. The company has research collaboration agreement with OPKO Biologics, Inc. Entera Bio Ltd. was incorporated in 2009 and is headquartered in Jerusalem, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.